Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
1. Measured by its binding ability in a functional ELISA. Immobilized human IGF2 at 10 µg/mL (100 µl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 18 ng/mL. 2. Measured by its binding ability in a functional ELISA. Immobilized human IGF1 at 10 µg/mL (100 µl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 24 ng/mL. 2. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human bre
Lyophilized PBS, pH 7.4
Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles.
IGFBP3 Protein, Binding protein 29 Protein, Binding protein 53 Protein, BP-53 Protein, IGF-binding protein 3 Protein, IGFBP-3 Protein, IBP-3 Protein, IBP3 Protein
IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.